Editorial Podcasts

This episode of Pharma Pulse discusses new research linking severe COVID-19 to increased stroke risk among asthma patients, a KFF poll showing divided parental support for vaccine-related agendas, and US News & World Report’s 2026 list of top Medicare Advantage and Part D plan providers.

This episode of Pharma Pulse discusses new research revealing persistent disparities in women’s cancer outcomes, record-high physician pay amid steady productivity, and AstraZeneca’s major Texas expansion to double production of its hyperkalemia treatment, Lokelma.

This episode of Pharma Pulse covers the FDA’s approval of a rapid one-minute HIV self-test, the US government’s decision to delay tariffs on pharmaceutical exports from Singapore, and CVS Pharmacy’s acquisition of more than 600 Rite Aid stores across three states to expand its community health footprint.

This episode of Pharma Pulse covers the nationwide Kaiser Permanente strike involving more than 40,000 healthcare workers, Takeda’s new AI-driven antibody discovery partnership with Nabla Bio, and the FDA’s OAI designation for Novo Nordisk’s Bloomington manufacturing facility.

This episode of Pharma Pulse covers how recent CDC layoffs are fueling concerns about disease surveillance, Ypsomed’s new autoinjector manufacturing site in North Carolina, and Lupin’s $250 million investment to build a respiratory and specialty drug facility in Florida.

This episode of Pharma Pulse covers how Mark Cuban’s direct-to-consumer pharmacy is challenging traditional drug pricing models, AstraZeneca’s $4.5 billion investment to expand its Virginia manufacturing site, and Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics to advance RNA-based medicines.

This episode of Pharma Pulse covers the CDC’s new individualized approach to COVID-19 vaccination and changes to chickenpox guidance for toddlers, new research showing how GLP-1 therapies can interfere with PET-CT imaging results, and the Third Circuit Court’s rejection of Novo Nordisk’s IRA challenge.

This episode of Pharma Pulse covers the FDA’s approval of golimumab for pediatric ulcerative colitis, AstraZeneca’s new multi-target neuroscience partnership with Algen, and Peli BioThermal’s acquisition of Evo to strengthen its global cold chain portfolio.

This episode of Pharma Pulse covers new research showing how obesity at age 20 increases postpartum diabetes risk, Amgen’s new direct-to-consumer digital platform aimed at improving treatment access, and Eli Lilly’s $1 billion investment to strengthen manufacturing in India.

This episode of Pharma Pulse covers the FDA’s quiet approval of the first generic mifepristone tablet, Takeda’s decision to discontinue cell therapy research programs, and SciSafe’s expansion of biopharma storage capacity with a new East Brunswick, New Jersey facility.

This episode of Pharma Pulse covers the potential ramifications of a federal government shutdown on FDA operations, Aetna’s newly announced 2026 Medicare Advantage offerings, and new research showing maternal and child mortality rates in the US remain higher than in most high-income nations.

This episode of Pharma Pulse covers ATA’s warning that telehealth protections are critical to maintaining care access during a potential federal shutdown, new KFF data showing the rapid rise of Medicare Advantage special needs plans, and Halozyme’s $750 million acquisition of Elektrofi to expand its drug delivery portfolio.

This episode of Pharma Pulse covers the Trump administration’s plan to launch a government-run healthcare website for patients, new data showing gabapentin has become the fifth most prescribed drug in community pharmacies, and promising trial results from a novel gene therapy that slows the progression of Huntington’s disease.

This episode of Pharma Pulse covers new data showing measles vaccine coverage remains below herd immunity thresholds, the FDA’s approval of guselkumab for pediatric plaque psoriasis and psoriatic arthritis, and AbbVie breaking ground on a new API manufacturing site in Illinois.

This episode of Pharma Pulse covers the Trump administration’s 100% tariff on branded drug imports, new research linking pediatric influenza to neurological complications amid vaccination gaps, and AbbVie’s FDA submission for tavapadon, a potential new treatment for Parkinson’s disease.

This episode of Pharma Pulse covers new research showing Medicaid cuts could widen pediatric coverage gaps, clinical trial data on a fixed-dose combination therapy lowering heart failure risk in type 2 diabetes, and Bristol Myers Squibb’s launch of a direct-to-patient program for Sotyktu to improve psoriasis treatment access.

This episode of Pharma Pulse covers the CDC’s unanimous vote to broaden COVID-19 vaccine recommendations for all adults, new data showing the Medicare Part D Senior Savings Model lowers insulin costs and improves care, and Eli Lilly’s investment in a new Houston manufacturing facility to support its fast-growing pipeline.

This episode of Pharma Pulse covers the FDA’s review of a possible link between prenatal acetaminophen use and autism, GSK’s supplemental new drug application to update leucovorin labeling, and Celltrion’s acquisition of an Eli Lilly production facility to expand biologics manufacturing capacity.

This episode of Pharma Pulse covers ACIP’s move toward shared decision-making for COVID-19 vaccines, Pfizer’s acquisition of Metsera to strengthen its obesity and cardiovascular pipelines, and Closed Loop Medicine’s partnership with Wedosify to improve patient adherence to GLP-1 therapies.

This episode of Pharma Pulse covers the CDC’s decision to postpone changes to Hepatitis B vaccine guidance, new research showing value-based care improves visit frequency and consistency for seniors, and Takeda’s partnership with VELA to launch wind-powered transport for medicines.

This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.

This episode of Pharma Pulse covers the former CDC director’s claim she was dismissed for refusing to prioritize ideology over evidence, new findings that physician mental health remains a serious concern, and Eli Lilly’s $5 billion investment in a new Virginia manufacturing plant to expand biologics production.

This episode of Pharma Pulse covers new data showing 1 in 6 US parents are delaying or skipping childhood vaccinations, Secretary Robert F. Kennedy Jr.’s move to expand a federal vaccine advisory committee, and survey findings that more than half of healthcare workers are considering leaving their current roles.

This episode of Pharma Pulse covers healthcare advocates’ push for a $50 billion Rural Health Transformation Program, new research showing pneumococcal vaccination gaps among adults with celiac disease, and Novartis’ $5.7 billion licensing agreement with Monte Rosa Therapeutics for protein degrader therapies.

This episode of Pharma Pulse covers new FDA guidance to speed development of non-opioid pain treatments, the FTC’s warning against non-compete agreements for doctors and nurses, and DHL Supply Chain’s acquisition of SDS Rx to strengthen last-mile healthcare delivery.

This episode of Pharma Pulse covers reports of a White House executive order to restrict treatments discovered in China, new data showing robust immune responses from Pfizer and BioNTech’s COVID-19 vaccine in high-risk adults, and Samsung Biologics’ latest US manufacturing deal amid tariff uncertainty.

This episode of Pharma Pulse covers Florida’s plan to roll back school vaccine mandates amid a measles outbreak, President Trump’s renewed focus on limiting direct-to-consumer pharma advertising, and ICER’s latest cost-effectiveness analysis of GLP-1 obesity treatments semaglutide and tirzepatide.

This episode of Pharma Pulse covers Novartis’ acquisition of Tourmaline Bio to advance its cardiovascular candidate Pacibekitug, new research uncovering biological and immunological factors driving flu severity in older adults, and strategies to address the top five reasons patients don’t take their medications.